Access to essential drugs in poor countries: A lost battle?

JAMA

Volumn 281, Issue 4, 1999, Pages 361-367

  Pécoul, Bernard ^a   Chirac, Pierre ^a   Trouiller, Patrice ^a   Pinel, Jacques ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B LIPID COMPLEX; ANTHELMINTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ANTISCHISTOSOMAL AGENT; ANTITRYPANOSOMAL AGENT; ARTEMETHER; ATOVAQUONE PLUS PROGUANIL; BCG VACCINE; BENZNIDAZOLE; CEFTRIAXONE; CIPROFLOXACIN; EFLORNITHINE; HALOFANTRINE; IVERMECTIN; MEFLOQUINE; MEGLUMINE ANTIMONATE; MELARSOPROL; NIFURTIMOX; OXAMNIQUINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PRAZIQUANTEL; RIFAMPICIN; SURAMIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ARTICLE; BACTERIAL MENINGITIS; DEVELOPING COUNTRY; DRUG COST; DRUG MARKETING; DRUG QUALITY; DRUG RESEARCH; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HELMINTHIASIS; LEISHMANIASIS; MALARIA; ONCHOCERCIASIS; PRIORITY JOURNAL; SCHISTOSOMIASIS; SHIGELLOSIS; TUBERCULOSIS;

EID: 0039830077     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.4.361     Document Type: Article

References (33)

1. World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva, Switzerland: World Health Organization; 1996. WHO Technical Report Series 863.
2. Pinel J, Varaine F, Fermon F, Marchant G, Marioux G. Des faux vaccins anti-meningocoque lors d'une epidemie de meningite au Niger. Med Maladies Infect. 1997;27:1-563.
3. World Health Organization. Fake drugs: a scourge on the system. WHO Drug Inf. 1995;9:127-129.
4. O'Brien KL, Selanikio GD, Hecdivert C, et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA. 1998; 279:1175-1180.
5. Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1997;2:839-845.
6. Pécoul B, Varaine F, Keita M, et al. Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. Lancet 1991;338:862-866.
7. World Health Organization. WHO response to meningitis epidemic in Africa, 1997. Bull Wkly Epidemiol Record. 1997;72:313-320.
8. Doua F, Boa FY, Schechter PJ, et al. Treatment of human late-stage gambiense trypanosomiasis with α-difluoromethylornithine (eflornithine). Am J Trop Med Hyg. 1987;37:525-533
9. Legros D, Enyaru JCK, Evans S, Maiso F. An outbreak of relapses among patients treated for T. b. gambiense trypanosomiasis in Arua, Northern Uganda. Paper presented at: 24th International Scientific Council for Trypanosomiasis Response and Control (ISC-TRC); September 1997; Maputo, Mozambique.
10. Coll-Seck A, Sylla A, Over M, et al. Implications of therapies for developing countries. Paper presented at: XII International Conference on AIDS; June 28-July 3, 1998; Geneva, Switzerland.
11. Centers for Disease Control and Prevention. Mortality From Dysentery in Africa: A Follow-up Study in Burundi. Atlanta, Ga: Centers for Disease Control and Prevention; 1993. CDC internal report.
12. Paquet C, Perea W, Grimont F, et al. Aetiology of haemorragic colitis epidemic in Africa. Lancet. 1993; 342:175.
13. Paquet C, Leborgne P, Sasse A, Varaine F. An outbreak of Shigella dysenteriae type 1 dysentery in a refugee camp in Rwanda. Sante. 1995;5:181-184.
14. Paquet C, Van Soest M. Mortality and malnutrition among Rwandan refugees in Zaïre. Lancet. 1994; 344:823-824.
15. Essential Drugs Price List. Copenhagen, Denmark: UNICEF Supply Division; 1995.
16. Varaine F, Keita M, Kaninda AV, et al. Long acting chloramphenicol versus ceftriaxone for treatment of bacterial meningitis in children aged 2-35 months. Paper presented at: Eighth International Congress on Infectious Diseases; May 15-18, 1998; Boston, Mass.
17. World Health Statistics Annual 1996. Geneva, Switzerland: World Health Organization; 1998.
18. Tandon BN, Acharya A, Tandon A. Epidemiology of hepatitis B virus infection in India. Epidemiol Infect. 1996;117:313-325.
19. Kaddar M. La mutation du marché mondial des vaccins. Rev Prescrire. 1995;157:844-847.
20. Crofton J, Chaulet P, Maher D. Principes pour la prise en charge de la tuberculose à bacilles résistants. Geneva, Switzerland: World Health Organization; 1997. WHO/TB/96.210 (rev 1).
21. Trouiller P. Recherche et développement pharmaceutiques en matière de maladies transmissibles dans la zone intertropicale. Sante. 1996;6:299-307.
22. Trouiller P, Rey JL, Olliaro P. Analysis of drug development patterns of six tropical diseases between 1975 and 1997. Paper presented at: Eighth International Congress on Infectious Diseases; May 15-18, 1998; Boston, Mass.
23. Grabowski H. The effect of pharmacoeconomics on company research and development decisions. Pharmacoeconomics. 1997;5:389-397.
24. International Strategies for Tropical Diseases Treatments: Experiences With Praziquantel. Boston, Mass: Harvard School of Public Health; 1996.
25. World Health Organization. Counterfeit Drugs: Report of a WHO/IFPMA Workshop. Geneva, Switzerland: World Health Organization; 1992. WHO/ DMP/CFD/92.
26. World Health Organization. Recommendations from the ICDRA reinforce the mission of regulatory authorities. WHO Drug Information. 1996;4:182-185
27. Correa C. The Uruguay Round and Drugs. Geneva, Switzerland: World Health Organization; 1997.
28. Intellectual Property Patents and Pharmaceuticals. Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations; 1997.
29. Lanjouw JO. The Introduction of Pharmaceutical Product Patents in India: Heartless Exploitation of the Poor and Suffering? Cambridge, Mass: National Bureau of Economic Research; 1998.
30. Rozek RP, Berkowitz R. The Effects of Patent Protection on the Prices of Pharmaceutical Products. White Plains, NY: National Economic Research Associates; 1998.
31. Tropical Disease Research. From Investigation to Eradication: Tropical Diseases Research Twelfth Programme Report. Geneva, Switzerland: World Health Organization; 1995:9-36.
32. Olliaro P. Will the fight against tropical diseases benefit from orphan drug status? Trop Med Int Health. 1997;2:113-115.
33. Velasquez G, Boulet P. Globalization and Access to Drugs: Implications of the WTO/TR/PS Agreement. Geneva, Switzerland: World Health Organization; 1998.